The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both
normal and pathological angiogenesis, has revealed innovative therapeutic approaches in …

Treatment options for retinal diseases, such as neovascular age-related macular
degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded …

Background Age‐related macular degeneration (AMD) is the most common cause of
uncorrectable severe vision loss in people aged 55 years and older in the developed world …

Background Ranibizumab—a recombinant, humanized, monoclonal antibody Fab that
neutralizes all active forms of vascular endothelial growth factor A—has been evaluated for …

Purpose Recent reports have described a spectrum of uncommon findings of intraocular
inflammation (IOI), retinal vasculitis and/or retinal vascular occlusion in patients with …

Age-related macular degeneration (AMD) is a disease leading to severe visual loss and
legal blindness in the elderly population. Its pathogenesis, likely multifactorial, involving a …

Diabetic retinopathy remains the leading vascular-associated cause of blindness throughout
the world. Its treatment requires a multidisciplinary interventional approach at both systemic …

PURPOSE: To evaluate an optical coherence tomography (OCT)-guided, variable-dosing
regimen with intravitreal ranibizumab for the treatment of patients with neovascular age …

Purpose: To report the rates of endophthalmitis and the spectrum of causative organisms
after intravitreal injection of anti-vascular endothelial growth factor agents and possible …

PURPOSE: To evaluate the efficacy and safety of ranibizumab administered monthly for
three months and then quarterly in patients with subfoveal choroidal neovascularization …